Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis

scientific article published on 09 March 2012

Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S12325-012-0007-Y
P698PubMed publication ID22411424
P5875ResearchGate publication ID221697274

P50authorCrystal WatsonQ91334881
P2093author name stringMachaon M K Bonafede
Kathleen M Fox
Shravanthi R Gandra
Nicole Princic
P2860cites workDevelopment of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-upQ46389803
The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985.Q50639396
Psoriasis: epidemiology, clinical features, and quality of lifeQ24675003
Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims dataQ31116692
Epidemiology of spondyloarthritis in North AmericaQ34717134
A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugsQ35638528
Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologistsQ37085249
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologicsQ37142442
Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care populationQ37484466
Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practiceQ45159990
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectpatientQ181600
adalimumabQ348260
P304page(s)234-248
P577publication date2012-03-09
P1433published inAdvances in TherapyQ4686392
P1476titleCost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis
P478volume29

Reverse relations

cites work (P2860)
Q36942901Analysis and Breakdown of Overall 1-Year Costs Relative to Inpatient and Outpatient Care Among Rheumatoid Arthritis Patients Treated with Biotherapies Using Health Insurance Claims Database in Alsace
Q33572758Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends
Q57169149Biosimilars: Review of current applications, obstacles, and their future in medicine
Q37452967Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study
Q53119214Comparing biologic persistence and healthcare costs in rheumatoid arthritis patients initiating subcutaneous biologics.
Q36942874Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic
Q34211985Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population
Q37583028Cost-of-illness and quality of life in patients with ankylosing spondylitis at a tertiary hospital in Korea.
Q37453002Costs of Drug Therapy in Patients with Ankylosing Spondylitis in Brazil
Q36274355Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis
Q38068578Emerging drugs for axial spondyloarthritis including ankylosing spondylitis
Q38166016Emerging drugs for the treatment of uveitis
Q51039528Funding a smoking cessation program for Crohn's disease: an economic evaluation.
Q41122444Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.
Q36576535Hepatotoxicity Associated with the Use of Anti-TNF-α Agents
Q37284234Pharmacogenomics in clinical practice and drug development
Q91918289Real world, big data cost of pharmaceutical treatment for rheumatoid arthritis in Greece
Q58563236Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
Q40942139The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
Q38207916Treatment of psoriasis: focus on clinic-based management with infliximab